<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>60</patient-age><report-id>US-ELI_LILLY_AND_COMPANY-US201201004141</report-id><gender>female</gender><reactions><reaction>normal blood sugars range 110-120 but they have been 150-180</reaction><reaction>lack of drug effect</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>HUMALOG LISPRO</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Diabetes mellitus</indication></indications><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734883_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151008</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>US-ELI_LILLY_AND_COMPANY-US201201004141</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-01-06</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-14</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-ELI_LILLY_AND_COMPANY-US201201004141</companynumb>
		<linkedreport>
			<linkreportnumb>US201108008319</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>US201210008601</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Tim</reportergivename>
			<reporterfamilyname>Boersma</reporterfamilyname>
			<reporterstreet>501 South Grace Street</reporterstreet>
			<reportercity>Addison</reportercity>
			<reporterstate>IL</reporterstate>
			<reporterpostcode>60101</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reportertitle>Ms.</reportertitle>
			<reportergivename>Carla</reportergivename>
			<reporterfamilyname>Hoeft</reporterfamilyname>
			<reporterstreet>839 Lockwood Circle</reporterstreet>
			<reportercity>Naperville</reportercity>
			<reporterstate>IL</reporterstate>
			<reporterpostcode>60563</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>CH</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19510531</patientbirthdate>
			<patientweight>81.633</patientweight>
			<patientheight>168</patientheight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cerebrovascular accident</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>201103</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>affected left side, only had use of one arm and one leg; handicap</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>201103</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>normal blood sugars range 110-120 but they have been 150-180</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hyperglycemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hyperglycaemia</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201112</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>lack of drug effect</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201112</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>A867101A</drugbatchnumb>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugstructuredosagenumb>48</drugstructuredosagenumb>
				<drugstructuredosageunit code="025"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>48 u, qd</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Diabetes mellitus</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2011-05-01</drugstartdate>
				<actiondrug code="6">Not Applicable</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>UNK, tid</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<actiondrug code="6">Not Applicable</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>who <Semaphore x="1802982" class="Disease or Finding" value="Communication Disorder" score="1.00" ID="C2958">contacted </Semaphore>the company to report a <Semaphore x="3204997" class="MedDRA LLT" value="Product quality issue" score="1.00" ID="10069327">product complaint</Semaphore>, <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a <Semaphore x="1387834" class="Patient Age" value="59" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="59" score="1.00" ID="">59 </Semaphore>year old </Semaphore><Semaphore x="2441774" class="Race" value="Race" score="1.00" ID="C17049">Caucasian </Semaphore>female patient.Medical history included a <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke </Semaphore>in Mar 2011, followed by a <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>of <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore>during that <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>. The <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke </Semaphore>affected her left side and she only had use of one <Semaphore x="1543524" class="AnatomicStructure" value="Arm" score="1.00" ID="C32141">arm </Semaphore>and one <Semaphore x="2104605" class="AnatomicStructure" value="Leg" score="1.00" ID="C32974">leg</Semaphore>. The patient reported at follow up she was <Semaphore x="2909520" class="MedDRA LLT" value="Disability" score="1.00" ID="10013050">handicap </Semaphore>following the <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke</Semaphore>. Concomitant medication were not provided.The patient began using <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>(<Semaphore x="669768" class="Medicine" value="Humalog" score="0.49" ID="228096">Humalog</Semaphore>) via a disposable KwikPen device beginning on an unspecified date, subcutaneously, dosed by sliding <Semaphore x="2497356" class="AnatomicStructure" value="Scalene Lymph Node" score="1.00" ID="C89780">scale </Semaphore>three times daily, 48 units a day for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes</Semaphore>. It was reported the patient initiated <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore><Semaphore x="2588121" class="Disease or Finding" value="Stroke During Hospitalization" score="1.00" ID="C80478">during <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>following her <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke</Semaphore></Semaphore>. Upon follow up, the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>stated <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>was started in May 2011. On 06-Dec 2011, seven months after initiating <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro</Semaphore>, the patient received a new box of KwikPen devices and had been having a <Semaphore x="1849470" class="Procedure" value="Difficulty Concentrating Reading Newspaper or Watching Television" score="1.00" ID="C104307">difficult </Semaphore>time with them. While using these pens her <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>sugar was between 150 and 180 when her normal <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>sugar range was 110 to 120 (units not provided) (<Semaphore x="3204997" class="MedDRA LLT" value="Product quality issue" score="1.00" ID="10069327">product complaint </Semaphore>12003795/ Lot A867101A for the box). The patient changed to a new box of pens and her <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>sugar was then <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore>(resolved). The patient was not hospitalized due to the event. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>reported the <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>as <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia </Semaphore>and ineffective <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">control</Semaphore>. <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">Insulin </Semaphore>lispro </Semaphore>continued.It was not provided if the patient was a trained user of the device. A friend of the patient who was a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore><Semaphore x="1550141" class="Procedure" value="Assisted Labor" score="1.00" ID="C92738">helped </Semaphore>her. The general device duration of use was not provided. The duration of use of the box of suspect devices was about one month. Use of KwikPen device continued via a new box of pens. Return status of the suspect devices was unknown.The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>thought that the event of <Semaphore x="2806733" class="MedDRA LLT" value="Blood glucose increased" score="1.00" ID="10005557">increased <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.74" ID="269493">glucose </Semaphore></Semaphore>was very likely related to <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>because it was bad and not stored properly before purchase. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>thought the <Semaphore x="2914105" class="MedDRA LLT" value="Drug ineffective" score="1.00" ID="10013709">lack of <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>effect </Semaphore>was related to the <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>because the <Semaphore x="2806733" class="MedDRA LLT" value="Blood glucose increased" score="1.00" ID="10005557">increased <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.74" ID="269493">glucose </Semaphore></Semaphore>resolved after the patient got a new package.Update 16-Jan 2012: Information received on 06-Jan 2012 was determined to be new clinical episode to US201108008319. All information regarding new clinical episode has been added to this case. Patient link to case US201108008319.Update 06-Feb 2012: Additional information received from the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 03-Feb 2012. Added patients <Semaphore x="2441774" class="Race" value="Race" score="1.00" ID="C17049">race</Semaphore>, <Semaphore x="3320545" class="MedDRA LLT" value="Weight" score="1.00" ID="10047890">weight</Semaphore>, and height. Added start date of <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro</Semaphore>. Added <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physicians </Semaphore>opinion of relatedness and <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis</Semaphore>. Case and narrative updated with new information accordingly.Update 14-Feb 2012: Upon review removed start date of May 2011 that was provided by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>as it <Semaphore x="2423624" class="Procedure" value="Prior Adjuvant Chemotherapy" score="1.00" ID="C15564">preceded </Semaphore>the patients <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke</Semaphore>. Case and narrative updated accordingly.Update 24-Jan 2013: Additional information was received on 14-Jan 2013 from the reporting <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>and from the patient. Patient reporter was added; phone number was added to patient information; medical history of <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke </Semaphore>and <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore>was added with dates; start date of <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>was added <Semaphore x="1563494" class="AnatomicStructure" value="Back" score="1.00" ID="C13062">back </Semaphore>to case from previous follow up; serious event of <Semaphore x="2850691" class="MedDRA LLT" value="Cerebrovascular accident" score="1.00" ID="10008190">stroke </Semaphore>was removed; case was downgraded to non serious and case narrative was updated to reflect additional information provided.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>